Mass General Brigham researchers found that the intensive cholesterol-lowering therapy evolocumab reduced the risk of a first major cardiovascular event in high-risk patients who did not have known atherosclerosis (the build-up of plaque inside artery walls) but did have diabetes. Results were presented at the American College of Cardiology’s Annual Scientific Session & Expo and simultaneously published in JAMA.
This article was originally published on MedicalXpress.com
Almost half of all Canadians regularly take at least one nutritional supplement such as vitamins, minerals, fibre supplements, antacids and fish oils. Many of these individuals are healthy and hoping to improve general well-being or prevent chronic […]
By Daniel Zane Bryant, author of “Living with Food Allergies: A Complete Lifestyle Guide” (available on Amazon at https://www.amazon.com/dp/B0G2BcGB2K) Navigating food allergies might initially feel overwhelming, yet it presents an exciting opportunity to reimagine familiar […]
What Are Boundaries? As the word portrays, boundaries in a relationship help each person establish expectations with their partner. Boundaries can help you communicate what you are comfortable with and what you are willing to […]
© 2025 SimplyWell.ca